Table 2 Patient characteristics.
Total number of patients | 81 |
Sex ratio (f:m) | 31:50 |
Tumor subgroups | |
Anaplastic astrocytomas (AIII) | 5 |
Anaplastic oligodendrogliomas (OIII) | 44 |
Anaplastic mixed gliomas (mixed III) | 14 |
Glioblastomas (GBM) | 18 |
Tumor location | |
Frontal | 40 (49.4%) |
Fronto-parietal | 1 (1.2%) |
Fronto-temporal | 4 (5.0%) |
Temporal | 16 (19.8%) |
Temporo-parietal | 2 (2.5%) |
Parietal | 13 (16.0%) |
Parieto-occipital | 1 (1.2%) |
Occipital | 3 (3.7%) |
Diencephalic | 1 (1.2%) |
Antiepileptic treatment, Y/N | 60/21 |
Median age at the time of RT (range) | 48 years (18;69) |
Median follow-up time after RT (range) | 78.8 mo. (22.3–285.8 m) |
RT only | 28 (34.6%) |
Concomitantt RT | 17 (21.0%) |
CT following RT | 36 (44.4%) |
Smokers (Y/N/n.a.) | 12/26/43 |
Patients with arterial hypertension (Y/N/n.a) | 11/57/13 |
Patients with diabetes (Y/N/n.a) | 5/63/13 |
Patients with hypercholesterolemia (Y/N/n.a) | 10/58/13 |
Number of patients with leukoencephalopathy (LCP) | 44 |
Median time to LCP (range) | 14.9 m (1.2–180.6 m) |
Median follow-up time after LCP onset | 59.5 m (16.2–183.1 m) |
Number of patients with clinical symptoms | 32 |
Cognitive impairment | 28 |
Gait disturbance | 12 |
Urinary incontinence | 9 |
Median time to symptoms after RT (range) | 39.4 m (4.7–146.1 m) |
